SCHEMBL4885688

SCHEMBL4885688

Cc1nc(C(=O)Nc2ccc(N(C#N)CCO[Si](C)(C)C(C)(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
F10 P00742 2/20 0.35
GRM5 P41594 2/20 0.34
TRPV4 Q9HBA0 1/20 0.34
NPC1 O15118 5/20 0.34
ALDH1A1 P00352 3/20 0.34
NFKB1 P19838 2/20 0.34
NFKB2 Q00653 2/20 0.34
RELA Q04206 2/20 0.34
LMNA P02545 2/20 0.34
CASP3 P42574 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
TP53 P04637 2/20 0.34
TSHR P16473 2/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4881051 0.88 RAB9A (0.38) RAB9ASMN1; SMN2L3MBTL1NPC1ALDH1A1
SCHEMBL4876097 0.85 F10 (0.38) RAB9ASMN1; SMN2F10NPC1ALDH1A1
SCHEMBL4873941 0.85 GRM5 (0.40) RAB9ASMN1; SMN2L3MBTL1F10GRM5
SCHEMBL14066579 0.85 GRM5 (0.40) RAB9ASMN1; SMN2L3MBTL1F10GRM5
SCHEMBL4880879 0.83 RAB9A (0.37) RAB9ASMN1; SMN2L3MBTL1NPC1ALDH1A1
SCHEMBL4878081 0.80 KMT2A (0.38) RAB9ASMN1; SMN2L3MBTL1NPC1ALDH1A1
SCHEMBL4881302 0.78 KMT2A (0.38) RAB9ASMN1; SMN2L3MBTL1NPC1ALDH1A1
SCHEMBL4879114 0.77 F2 (0.38) RAB9AF10NPC1
SCHEMBL4881646 0.77 DGAT1 (0.33) L3MBTL1ALDH1A1
SCHEMBL4878069 0.76 SMN1; SMN2 (0.35) RAB9ASMN1; SMN2F10NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080214533-A1 Cyclic Iminocarbamates And Their Use BAYER HEALTHCARE AG (DE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214533-A1 Cyclic Iminocarbamates And Their Use F2, UQCRB, F12 RAB9A 2655/4885SMN1; SMN2 2534/4885L3MBTL1 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.